Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): ...

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Vir Biotechnology (VIR – Research Report) today and set a price target of ...

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

August Global Partners will assist Gene Solutions in enhancing the performance of their oncology solutions by providing ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...

Vir Biotechnology, Inc. (NASDAQ:VIR – Get Free Report) saw some unusual options trading on Wednesday. Stock traders purchased 6,929 call options on the stock. This is an increase of approximately 933% ...

Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...